Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.

Slides:

Advertisements

Similar presentations

The role of post granulocyte colony-stimulating factor white blood cell counts in predicting the mobilization adverse events and yields Shu-Huey Chen1,2.

Advertisements

Second Donation from Volunteer Hematopoietic Stem Cell Donors in Taiwan Tso-Fu Wang(1), Shu-Huey Chen(1), Shang-Hsien Yang(1), Chu-Yu Chang(2), Ya-Wen.

Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

AML Clinical Presentation. Clinical Presentation: Symptoms Fatigue (50%) Anorexia and weight loss Fever with or without an identifiable infection (10%)

Alexander H. Schmidt, Thilo Mengling, Camila J

Autologous Peripheral Blood Stem Cell Rescue. Multiple Myeloma.

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation Karen Ballen, Kwang Woo Ahn, Min Chen, Hisham.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.

Human Health and Disease

Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation

Peripheral Blood Stem Cell Rescue. Multiple Myeloma.

Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation Abraham Guerrero,

Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.

Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program by Michael.

by Karthik A. Ganapathi, Danielle M. Townsley, Amy P. Hsu, Diane C

The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes Nancy H. Collins,

Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are.

Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program John P. Miller, Elizabeth H. Perry, Thomas H.

Health-related Quality of Life of Bone Marrow versus Peripheral Blood Stem Cell Donors: A Prespecified Subgroup Analysis from a Phase III RCT—BMTCTN Protocol.

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Peripheral Blood Stem Cell Rescue. Multiple Myeloma.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population by Sumithira Vasu,

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G- CSF and Plerixafor Compared to G-CSF and Cyclophosphamide Paul Shaughnessy,

Figure 2 Components of each transplantation platform

Pain, Donation-Related Symptoms and the Trajectory of Recovery in Children after Bone Marrow (BM) Donation Are Influenced By Age (Pre vs. Post-Puberty)

Related PBSC Donors Experience Higher Levels of Pain and Donation-Related Symptoms and Less Complete Rates of Recovery Compared to Unrelated Donors:

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Vivian.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma Marcel P. Devetten,

Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony–Stimulating Factor in Lymphoma Patients Undergoing Autologous.

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan,

Jo-Anne H. Young, Brent R. Logan, Juan Wu, John R. Wingard, Daniel J

Motivations, Experiences, and Perspectives of Bone Marrow and Peripheral Blood Stem Cell Donors: Thematic Synthesis of Qualitative Studies Maria C. Garcia,

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era Navneet S. Majhail, Pintip Chitphakdithai,

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.

High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem.

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.

Comparison of absolute counts for a, b) white blood cells (WBC), c, d) neutrophils, e, f) monocytes, and g, h) eosinophils for 100 patients with lymphangioleiomyomatosis.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International.

Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients by Erica B. Esrick, John P. Manis,

Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors Annelies Billen, J. Alejandro Madrigal,

Race and Ethnicity Influences Collection of Granulocyte Colony–Stimulating Factor– Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Bridge to transplant following Bv+Bs regimen.

Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow.

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells by Yi-Bin Chen, Jennifer Le-Rademacher,

Mary Eapen Biology of Blood and Marrow Transplantation

Optimal Donor Selection: Beyond HLA

Stem cell transplant in MF: it’s time to personalize

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less David F. Stroncek, Bronwen E.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone.

Presentation transcript:

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program by Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Bronwen E. Shaw, John R. Wingard, Hillard M. Lazarus, Edmund K. Waller, Matthew Seftel, David F. Stroncek, Angela M. Lopez, Dipnarine Maharaj, Peiman Hematti, Paul V. O'Donnell, Alison W. Loren, Susan F. Leitman, Paolo Anderlini, Steven C. Goldstein, John E. Levine, Willis H. Navarro, John P. Miller, and Dennis L. Confer Blood Volume 121(1):197-206 January 3, 2013 ©2013 by American Society of Hematology

Donor blood counts at baseline, on the day of collection, and at postdonation follow-ups. Donor blood counts at baseline, on the day of collection, and at postdonation follow-ups. (A) Donor white blood cell (WBC) counts. (B) Donor platelet counts. (C) Donor hemoglobin levels. Minimum, lower quartile, median, upper quartile, maximum; day 5 is the first day of apheresis; Pre and Post refer to the apheresis procedure. Michael A. Pulsipher et al. Blood 2013;121:197-206 ©2013 by American Society of Hematology

Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period, and after donation. (Skeletal pain represents pain in at least 1 of the following sites: back, bone, headache, hip, limb, joint, and neck.) The severity of skeletal pain is defined as the maximum grade among these pain sites. Day 2 is the second day of filgrastim; day 5 is the first day of apheresis. (B) Sites of pain among BM and PBSC donors on the day noted to have the highest severity of pain (1-2 days post-BM collection and day + 5 from start of G-CSF for PBSC). Michael A. Pulsipher et al. Blood 2013;121:197-206 ©2013 by American Society of Hematology

Toxicities. Toxicities. (A) Highest toxicity level of key symptoms (fever in the absence of signs of infection, fatigue, skin rash, local reactions, nausea, vomiting, anorexia, insomnia, dizziness, and syncope) experienced by BM and PBSC donors at baseline, during pericollection period, and after donation. (Day 2 is the second day of filgrastim; day 5 is the first day of apheresis.) (B) Toxicities among BM and PBSC donors on the day noted to have the highest level of toxicity (1-2 days post-BM collection and day + 5 from start of G-CSF for PBSC). (C) Common toxicities among BM and PBSC donors on the day noted to have the highest level of toxicity (1-2 days post-BM collection and day + 5 from start of G-CSF for PBSC), and at selected time points after donation. Michael A. Pulsipher et al. Blood 2013;121:197-206 ©2013 by American Society of Hematology

Univariate probability of reported complete recovery from stem cell donation. Michael A. Pulsipher et al. Blood 2013;121:197-206 ©2013 by American Society of Hematology